Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Casandra

Casandra Test Code AR86577Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3000148CPT Code 81511

Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Also known as: MS SEQ2

Clinical Use

Order Test

Use

This second-trimester screening test is used to assess the risk of fetal conditions such as trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects. The test requires a previously submitted first-trimester specimen and nuchal translucency measurement carried out by a certified ultrasonographer. The risk assessment combines results from both the first and second trimesters, providing an integrated risk perspective for the conditions mentioned.

Special Instructions

The patient information from the first-trimester specimen is utilized for calculating the risk in this second-trimester test. The specimen must be drawn between 14 weeks and 24 weeks and 6 days of gestation, with the optimal window being between 16 and 18 weeks. Ensure a first trimester specimen, Maternal Screening, Sequential, Specimen #1, is performed prior to this test.

Limitations

This screening test does not provide a definitive diagnosis for fetal conditions. Rather, it assesses the probability of certain aneuploidy and neural tube defects based on maternal serum markers and nuchal translucency measurements. False positives and negatives are possible, and further diagnostic testing may be required. Factors such as maternal age, weight, ethnicity, and diabetic status are considered in the risk calculation, but inaccuracies in these parameters or gestational age may affect results.

Test Details

New York Approved